Fundraising Fox
TileBio
3 known investors
Find your way into TileBio
Sign up to see every warm intro you have to TileBio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the TileBio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
TileBio develops self-supervised AI foundation models for digital pathology, applied to cancer diagnosis, prognosis, biomarker discovery, and drug development. It serves clinicians, diagnostics, and pharmaceutical research by analysing pathology imaging and sequencing data.
Founders & leadership
CW
Christopher WalshCo-Founder / CEO & CTO
DC
David ChangCo-Founder / CMOHe holds a PhD in Medicine focused on pancreatic cancer from UNSW and brings expertise in genomics, transcriptomics, and molecular oncology from prior academic and research roles.
JL
John Le QuesneCo-Founder / CMOJohn Le Quesne is a clinician-scientist and histopathologist who leads a spatial biology facility at the CRUK Scotland Institute. He co-founded TileBio, a University of Glasgow spinout developing AI foundation models for computational pathology and precision cancer diagnostics.
Investors · 3
Twin Path Ventureslisted by Twin Path VenturesLondon · $952.5K
How we know: Twin Path Ventures's portfolio page · funding news · glasgowchamberofcommerce.com · Not right? Tell us
Scottish EnterprisereportedGlasgow
How we know: funding news · glasgowchamberofcommerce.com · Not right? Tell us
Also in the syndicate · 1
GU Holdings Ltd
Funding
SEC filings, press & company announcements- Undisclosed amountseedMar 2026
Twin Path Ventures (lead), GU Holdings Ltd, Scottish Enterprise
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Related companies · 7
TellBioTellBio is a biotechnology company founded by leading cancer researchers and clinicians from Harvard Medical School and Massachusetts General Hospital. The company focuses on oncology research and development, leveraging circulating tumor cell (CTC) technology and biomedical engineering.
ARTBIOARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue. The company covers the design, manufacture, and distribution of its therapies and builds on radiation research from the University of Oslo and Norway's Radium Hospital.
GentiBioGentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.
ChronicleBioTechbio company using multi-omic biobank data and AI to stratify patients with POTS, ME/CFS, Long COVID and other neuroimmune conditions.
TELA BioOffers soft tissue repair solutions combining naturally sourced tissue with polymer; lead product OviTex for hernia repair (NASDAQ: TELA), based in Malvern, PA.
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
ManifoldManifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs. The company develops a computational and experimental platform to optimize pharmacokinetics and biodistribution directly in living systems for drug discovery and development.
Companies working in the same space as TileBio.
Frequently asked questions
- What does TileBio do?
- TileBio develops self-supervised AI foundation models for digital pathology, applied to cancer diagnosis, prognosis, biomarker discovery, and drug development. It serves clinicians, diagnostics, and pharmaceutical research by analysing pathology imaging and sequencing data.
- Who founded TileBio?
- TileBio was founded by Christopher Walsh, Ke Yuan, David Chang, John Le Quesne.
- Who are TileBio's investors?
- TileBio's investors include Twin Path Ventures, Scottish Enterprise.